Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER)

Needham & Company LLC reaffirmed their hold rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Thursday,Benzinga reports.

Several other research firms also recently commented on OMER. Rodman & Renshaw started coverage on shares of Omeros in a report on Thursday. They issued a “buy” rating and a $9.00 price objective on the stock. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Omeros has a consensus rating of “Hold” and a consensus price target of $9.00.

Omeros Trading Down 2.9 %

NASDAQ:OMER opened at $6.75 on Thursday. The company has a market cap of $391.16 million, a PE ratio of -2.92 and a beta of 1.47. Omeros has a twelve month low of $1.38 and a twelve month high of $7.51. The company’s 50 day moving average is $4.14 and its two-hundred day moving average is $4.11.

Institutional Trading of Omeros

Several large investors have recently made changes to their positions in OMER. BNP Paribas Financial Markets lifted its stake in shares of Omeros by 75.5% in the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 12,951 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of Omeros in the 1st quarter valued at $85,000. Comerica Bank lifted its stake in shares of Omeros by 20.0% in the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 5,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Omeros by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after purchasing an additional 81,348 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.